title: [How to optimize the antiTNF alpha therapy in spondylitis?].
abstract: TNFalpha inhibitors have been a major advance in the treatment of spondyloarthropathies, having demonstrated their safety and efficacy, with higher response and survival rates than those observed in patients with rheumatoid arthritis. The fact that disease modifying anti-arthritic drugs (DMARD) have shown utility in the treatment of this disease, especially in the axial forms, gives them greater importance, since it is known that up to 30%of patients do not respond to treatment with non-steroidal anti-inflammatory drugs. However, we must take into account that these drugs are expensive and not without side effects, so it is necessary to optimize their use. We intend to review the use of antiTNF alpha in spondyloarthropathies and review the available evidence on strategies that can help with their rational use.
authors.affiliation: Servicio de Reumatología, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, España. mcasvi@yahoo.es
authors.forename: Maria del Carmen
authors.initials: Mdel C
authors.lastname: Castro Villegas
authors.forename: Alejandro
authors.initials: A
authors.lastname: Escudero Contreras
authors.forename: Maria Dolores
authors.initials: MD
authors.lastname: Miranda García
authors.forename: Eduardo
authors.initials: E
authors.lastname: Collantes Estévez
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy; D025241:Spondylarthritis / Q000150:complications / Q000188:drug therapy*; D012460:Sulfasalazine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000150:complications / Q000188:drug therapy
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine